NJT Stock Overview

A clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. More details

NJT fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Earnings have grown 34.6% per year over the past 5 years

Risk Analysis

Does not have a meaningful market cap (€177K)

Makes less than USD$1m in revenue ($73K)

Shares are highly illiquid

Has less than 1 year of cash runway

+ 1 more risk

My Notes

Capture your thoughts, links and company narrative

RegenETP, Inc. Competitors

Bellicum Pharmaceuticals

BST:BPXA

€772.4k

Sangui Biotech International

HMSE:SBH

€419.8k

Epigenomics

DB:ECX

€1.2m

Medigene

XTRA:MDG1

€15.6m

Price History & Performance

Summary of share price highs, lows and changes for RegenETP
Historical stock prices
Current Share Price	US$0.036
52 Week High	US$0.07
52 Week Low	US$0.035
Beta	0.91
1 Month Change	0%
3 Month Change	0.56%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-59.55%

Recent updates

Shareholder Returns

	NJT	DE Biotechs	DE Market
7D	0%	5.5%	1.2%
1Y	n/a	-3.7%	10.1%

Return vs Industry: Insufficient data to determine how NJT performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how NJT performed against the German Market.

Price Volatility

Is NJT's price volatile compared to industry and market?
NJT volatility
NJT Average Weekly Movement	n/a
Biotechs Industry Average Movement	7.4%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.5%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: NJT has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine NJT's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	43	Richard Hague	www.polarityte.com

RegenETP, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services.

RegenETP, Inc. Fundamentals Summary

How do RegenETP's earnings and revenue compare to its market cap?
NJT fundamental statistics
Market cap	€162.82k
Earnings (TTM)	-€7.64m
Revenue (TTM)	€67.17k

2.4x

P/S Ratio

0.0x

P/E Ratio

Is NJT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NJT income statement (TTM)
Revenue	US$73.00k
Cost of Revenue	US$125.00k
Gross Profit	-US$52.00k
Other Expenses	US$8.25m
Earnings	-US$8.30m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-1.15
Gross Margin	-71.23%
Net Profit Margin	-11,376.71%
Debt/Equity Ratio	0%

How did NJT perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/12/04 18:47
End of Day Share Price	2023/09/06 00:00
Earnings	2023/03/31
Annual Earnings	2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

RegenETP, Inc. is covered by 11 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jonathan Aschoff	B. Riley Wealth
Kristen Kluska	Cantor Fitzgerald & Co.
Joshua Schimmer	Evercore ISI